Search

Supplementary Material 1

Additional file 1. Supplementary Methods and Figures S1–2. Figure S1. H3K4me3 landscapes in chidamide-resistant and chidamide-sensitive NKTL. Figure S2. JAK inhibitors overcome the resistance of SAHA/TSA in NKTL cells.

Additional file 1: Table S1. Database information and details of HER2 testing by study centre. Table S2. Sensitivity analysis of relapse-free survival and overall survival by HER2 and hormone receptor status. Figure S1. Flowchart of patients included in the ABCCG cohort analysis. Figure S2. Estimated heterogeneity between study centres in (A) relapse-free survival, and (B) overall survival (based on pooling univariable HR estimate from each centre with a random effect restricted maximum likelihood estimation model. HR, hazard ratio; I2, index of heterogeneity). Figure S3. Association of ERBB2 mRNA expression with HER2 IHC and ERBB2 CNV by hormone receptor status (TCGA-BRCA): (A-D) Hormone receptor-positive subgroup of TCGA-BRCA dataset: ERBB2 mRNA expression by (A) HER2-low and HER2-zero, (B) HER2 IHC score, (C) ERBB2 CNV; (D) ERBB2 CNV against HER2 IHC. (E-H) Hormone receptor-negative subgroup of TCGA-BRCA dataset: ERBB2 mRNA expression by (E) HER2-low and HER2-zero, (F) HER2 IHC score, (G) ERBB2 CNV; (H) ERBB2 CNV against HER2 IHC. Figure S4. Relapse-free survival by ERBB2 mRNA expression levels in combined TCGA-BRCA and METABRIC dataset (Quartile 1: lowest; Quartile 4: highest)

Additional file 2: Supplemental Table S1. Clinical and demographic characteristics of patients receiving chemotherapy.

Additional file 1: Supplemental Figure S1. Maintenance rituximab therapy and OS outcomes. (a) Maintenance rituximab in patients

Colorectal cancer (CRC) is the second leading cause of cancer-related deaths in the Western world. It is becoming increasingly clear that CRC is a diverse disease, as exemplified by the identification of subgroups of CRC tumours that are driven by distinct biology. Recently, a number of studies have begun to define panels of diagnostically relevant markers to align patients into individual subgroups in an attempt to give information on prognosis and treatment response. We examined the immunohistochemical expression profile of 18 markers, each representing a putative role in cancer development, in 493 primary colorectal carcinomas using tissue microarrays. Through unsupervised clustering in stage II cancers, we identified two cluster groups that are broadly defined by inflammatory or immune-related factors (CD3, CD8, COX-2 and FOXP3) and stem-like factors (CD44, LGR5, SOX2, OCT4). The expression of the stem-like group markers was associated with a significantly worse prognosis compared to cases with lower expression. In addition, patients classified in the stem-like subgroup displayed a trend towards a benefit from adjuvant treatment. The biologically relevant and poor prognostic stem-like group could also be identified in early stage I cancers, suggesting a potential opportunity for the identification of aggressive tumors at a very early stage of the disease. Refereed/Peer-reviewed